Low-Dose Naltrexone Presents New Options for Patients with Inflammatory, Autoimmune Diseases

In an interview at the Pharmacy Development Services 2022 conference, Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.

Traditionally used for patients with alcoholism or other forms of addiction, Denison said there is a growing body of case studies and research into the use of naltrexone for other treatments. Whereas the patented dosage is a 50 mg capsule, research is ongoing into the use of much smaller dosages. Denison also discussed the mechanism of action for naltrexone, how the evidence for naltrexone may differ from other bodies of research, and some adverse events that pharmacists should be aware of.